Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tgf-β2 antisense oligonucleotide
- Development stage
- Phase 1
- Lead developer
- Autotelic Bio
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intrathecal, Intracerebral Infusion, Intraventricular Infusion, Intravenous
01
Overview
tgf-β2 antisense oligonucleotide (also known as TGF-β2i or TASO) is an antisense oligonucleotide designed to downregulate the production of transforming growth factor-β2 (TGF-β2). In preclinical studies involving pancreatic cancer models, this drug has demonstrated the ability to enhance chemosensitivity to gemcitabine, suppress metastasis, and improve T-cell mediated anti-tumor activities. Its mechanism involves attenuating fibrotic reactions and suppressing regulatory T-cells, which facilitates the infiltration of cytotoxic T lymphocytes and increases pro-inflammatory cytokines, suggesting its potential as an immunotherapeutic intervention for pancreatic cancer.
- Other names
- TGF-Β2 isoform specific antisense oligonucleotide
02
Targets
TGFB2 (Transforming growth factor beta 2)
Beyond the preview
Go deeper on tgf-β2 antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tgf-β2 antisense oligonucleotide.